

B'SYS GmbH

**Ca<sub>v</sub>3.1 / Ca<sub>v</sub>3.3**  
**patch - clamp assay**

Specification Sheet

## TABLE OF CONTENTS

<b>1. INTRODUCTION.....</b>	<b>3</b>
<b>1.1 T-Type Calcium channels.....</b>	<b>3</b>
<b>2. MATERIAL AND METHOD.....</b>	<b>4</b>
<b>3. RESULTS .....</b>	<b>4</b>
<b>3.1 Biophysical Characterization.....</b>	<b>4</b>
<b>3.2 Pharmacological Characterization .....</b>	<b>5</b>
<b>4. ASSAY FLEXIBILITY.....</b>	<b>6</b>
<b>5. CONTACT INFORMATION .....</b>	<b>6</b>

## 1. INTRODUCTION

### 1.1 T-Type Calcium channels

T-type  $\text{Ca}^{2+}$  channels were originally called low-voltage-activated (LVA) channels because they can be activated by small depolarizations of the plasma membrane. In many neurons  $\text{Ca}^{2+}$  influx through LVA channels triggers low-threshold spikes, which in turn triggers a burst of action potentials mediated by  $\text{Na}^+$  channels. Burst firing is thought to play an important role in the synchronized activity of the thalamus observed in absence epilepsy, but may also underlie a wider range of thalamocortical dysrhythmias. In addition to a pacemaker role,  $\text{Ca}^{2+}$  entry via T-type channels can directly regulate intracellular  $\text{Ca}^{2+}$  concentrations, which is an important second messenger for a variety of cellular processes. Molecular cloning revealed the existence of three T-type channel genes. The deduced amino acid sequence shows a similar four-repeat structure to that found in high-voltage-activated (HVA)  $\text{Ca}^{2+}$  channels, and  $\text{Na}^+$  channels, indicating that they are evolutionarily related. Hence, the alpha1-subunits of T-type channels are now designated  $\text{Ca}_v3$ . Although mRNAs for all three  $\text{Ca}_v3$  subtypes are expressed in brain, they vary in terms of their peripheral expression, with  $\text{Ca}_v3.2$  showing the widest expression. The electrophysiological activities of recombinant Cav3 channels are very similar to native T-type currents and can be differentiated from HVA channels by their activation at lower voltages, faster inactivation, slower deactivation, and smaller conductance of  $\text{Ba}^{2+}$ .


## 2. MATERIAL AND METHOD

CHO cells were transfected with Cav3.1 or Cav3.3 cDNA. During the electrophysiological experiment they were continuously perfused with buffer solution: 137 mM NaCl, 4 mM KCl, 1.8 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM D-glucose, 10 mM HEPES, pH (NaOH) 7.40. The Pipette was filled with a solution containing: 135 mM CsF, 0.1 mM CaCl<sub>2</sub>, 5 mM NaCl, 54 mM CH<sub>3</sub>O<sub>3</sub>SCs, 2.25 mM MgCl<sub>2</sub>, 2 mM Na<sub>2</sub>ATP, 2.5 mM Creatine, 2.5 mM Phosphocreatine (disodium), 2.5 mM Pyruvate (free acid), 2.5 mM Oxalacetate, 17 mM HEPES, 7.5 mM EGTA, pH (CsOH) 7.2. After the seal was obtained cells were clamped to -80 mV.


## 3. RESULTS

### 3.1 Biophysical Characterization

Cav3.1 and Cav3.3 channel were biophysically characterized. The IV curves and the inactivation curves were recorded using voltage protocols given below. IV curves were normalized to the largest current amplitude, inactivation curves were normalized to the maximum of a Boltzmann function fit to the individual cells. Data were averaged and for the inactivation curves V<sub>0.5</sub> and the K values were determined.



**Fig.1:** Biophysical characterization of Cav3.1: left: representative current recording and applied voltage protocol, middle: IV curve, right: inactivation curve.



**Fig.2:** Biophysical characterization of Cav3.3: left: representative current recording and applied voltage protocol, middle: IV curve, right: inactivation curve.

**Table 1:** Summary of  $V_{0.5}$  and K values


	$V_{0.5}$ value	k value
Ca <sub>v</sub> 3.1	$-64.59 \pm 1.80$ mV	$7.09 \pm 0.18$
Ca <sub>v</sub> 3.3	$-60.67 \pm 1.96$ mV	$7.13 \pm 0.02$

### 3.2 Pharmacological Characterization


Mibefradil was used to validate the pharmacological properties of Ca<sub>v</sub>3.1 and Ca<sub>v</sub>3.3 channels. The following concentrations were tested:

Ca<sub>v</sub>3.1: 5 nM, 50 nM, 500 nM and 5000 nM

Ca<sub>v</sub>3.3: 50 nM, 500 nM, 1500 nM, 5000 nM and 50000 nM



**Fig.3:** Effect of Mibefradil on Ca<sub>v</sub>3.1 channels: left: representative current recording, right: dose response curve



**Fig.4:** Effect of Mibefradil on Ca<sub>v</sub>3.3 channels: left: representative current recording, right: dose response curve

**Table 2:** Summary of IC<sub>50</sub> values for Mibefradil

	IC <sub>50</sub> value	Hill coefficient	IC <sub>50</sub> Literature
Ca <sub>v</sub> 3.1	156.95 nM	0.87	251 nM – 1000 nM
Ca <sub>v</sub> 3.3	872.02 nM	1.33	1585 nM

## 4. ASSAY FLEXIBILITY

B'SYS offers its clients a high degree of flexibility. Client designed stimulation or application protocols can be transferred and validated within a short time.

## 5. CONTACT INFORMATION

- B'SYS GmbH  
Technology Center Witterswil  
Benkenstrasse 254  
4108 Witterswil  
Switzerland

Tel: +41 61 721 77 44  
Fax: +41 61 721 77 41  
Email: [info@bsys.ch](mailto:info@bsys.ch)  
Web: [www.bsys.ch](http://www.bsys.ch)